Ovagen: The Ovarian Bioregulator Tripeptide in Reproductive Aging Investigacion
Resumen Rápido
- What it is: Ovagen (Glu-Asp-Leu) is a synthetic tripeptide bioregulator designed to target ovarian tissue, from the Khavinson peptide series.
- Proposed mechanism: Hypothesized to modulate gene expression in ovarian cells through direct DNA/histone interaction, potentially influencing follicular development and ovarian reserve maintenance.
- Research claims: Preclinical studies report improved ovarian morphology, enhanced follicle preservation, and altered reproductive hormone profiles in aged animal models.
- Limitations: Extremely limited evidence base; all published studies from a single research group; no clinical trials.
- Status: Not FDA-approved. Not EMA-approved. Investigational with minimal evidence.
For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.
What Is Ovagen?
Ovagen is a synthetic tripeptide with the amino acid sequence Glu-Asp-Leu (glutamic acid-aspartic acid-leucine). It is the female reproductive system-targeted bioregulator in the Khavinson peptide series, designed to influence ovarian tissue biology. The compound was developed at the Saint Petersburg Institute of Bioregulation and Gerontology based on peptide fractions isolated from ovarian tissue extracts.
Ovarian aging — the progressive decline in oocyte quantity and quality — is one of the earliest and most consequential manifestations of biological aging in women. Ovarian reserve begins declining decades before menopause, and there are currently no proven interventions to slow this process. The development of ovarian-targeted bioregulators reflects an attempt to address this unmet medical need, though the evidence supporting Ovagen specifically remains preliminary. For an overview of the bioregulator class, see our guide to bioregulator peptides.
| Property | Detail |
|---|---|
| Peptide Name | Ovagen |
| Sequence | Glu-Asp-Leu |
| Amino Acids | 3 (tripeptide) |
| Molecular Weight | ~361 Da |
| Target Tissue | Ovarian (granulosa cells, follicles) |
| Origin | Khavinson bioregulator series |
| FDA Status | Not approved; not evaluated |
Mechanism of Action
Ovagen is proposed to operate through the standard Khavinson bioregulator mechanism — direct interaction with DNA and chromatin in ovarian cells to modulate gene expression. Specific proposed targets include genes involved in follicular development, granulosa cell function, anti-Mullerian hormone (AMH) production, and ovarian steroidogenesis.
- Follicle preservation: Ovagen is hypothesized to influence the rate of primordial follicle activation, potentially slowing the recruitment of dormant follicles and preserving ovarian reserve.
- Granulosa cell function: Published data suggest effects on granulosa cell proliferation and hormone production, including estradiol and AMH synthesis.
- Anti-apoptotic effects: Some studies report reduced apoptosis markers in ovarian tissue following Ovagen treatment, suggesting potential cytoprotective activity.
Research Findings
Animal Studies
The limited published research on Ovagen includes studies in aged female rats showing that Ovagen administration improved ovarian histological parameters, including increased numbers of healthy follicles and reduced atretic follicle counts compared to age-matched untreated controls. Some studies reported normalization of estrous cycle regularity and improved reproductive hormone profiles (FSH, LH, estradiol) in treated aged animals.
Cell Culture Studies
In vitro experiments using cultured ovarian granulosa cells have reported that Ovagen exposure increased cell proliferation rates and modulated expression of genes involved in steroidogenesis and follicular development. These studies typically used concentrations in the nanomolar to low micromolar range.
Critical Assessment
Ovagen has one of the thinnest evidence bases in the Khavinson bioregulator series. Published studies are few in number, originate from a single research group, and have not been independently replicated. The challenge of a tripeptide selectively targeting ovarian gene expression — while avoiding effects on other tissues — has not been mechanistically resolved. Given the complexity of ovarian biology and the critical importance of reproductive health decisions, the current evidence is insufficient to support any clinical conclusions about Ovagen's efficacy or safety.
Safety and Tolerability
No significant adverse effects have been reported in the limited published animal studies. As a simple tripeptide of common amino acids, direct toxicity is expected to be low. However, any compound claimed to influence ovarian function and reproductive hormone profiles warrants rigorous safety evaluation, particularly regarding effects on oocyte quality, embryo development, and endocrine disruption — none of which has been adequately studied for Ovagen.
Regulatory Status
Ovagen is not approved by any major regulatory agency. It is available through some specialty supplement suppliers but has not undergone clinical trials or regulatory review. Women considering any intervention targeting reproductive health should consult qualified reproductive endocrinologists.
Aviso Legal: Este artículo es solo para fines informativos y educativos. No constituye asesoramiento médico, diagnóstico o tratamiento. Consulta siempre con profesionales de la salud calificados antes de tomar decisiones sobre el uso de péptidos o cualquier protocolo relacionado con la salud.
Recibe Actualizaciones Semanales de Investigación de Péptidos
Mantente al día con las últimas investigaciones, guías y conocimientos sobre péptidos directamente en tu bandeja de entrada.
Sin spam. Cancela cuando quieras.